UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 28, 2008
________________
POZEN INC.
(Exact Name of Registrant as Specified in Charter)
________________
| | | | | |
| Delaware | | 000-31719 | | 62-1657552 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
1414 Raleigh Road, Suite 400 Chapel Hill, North Carolina | | 27517 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(919) 913-1030
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
________________
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Item 8.01. Other Events.
On April 28, 2008, POZEN Inc., a Delaware corporation (“POZEN”), issued a press release announcing the receipt of $20 million in milestone payments from GlaxoSmithKline in accordance with the Product Development and Commercialization Agreement dated as of June 11, 2003 for the approval by the U.S. Food and Drug Administration of the New Drug Application for Treximet(TM). A copy of POZEN’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| | | |
| Exhibit No. | | Description |
| 99.1 | | Press Release of POZEN Inc. dated April 28, 2008 reporting receipt of $20 million milestone payment from GlaxoSmiKline. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| POZEN INC. |
| | |
| By: | | /s/ William L. Hodges |
| Name: | | William L. Hodges |
| Title: | | Chief Financial Officer |
Date: May 1, 2008
